Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Imiquimod Topical Cream Clear all
Completed Phase 4 Interventional

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

NCT06840470
View directory record Official record
Conditions
Sebaceous Hyperplasia
Interventions
Imiquimod 5% Topical Cream
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

NCT00865644
View directory record Official record
Conditions
Neurofibromatosis Type 1, Cutaneous Neurofibromas
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

NCT00314756
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
imiquimod
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 21, 2026, 8:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Topical Imiquimod Treatment of Oral Dysplasia

NCT07210775
View directory record Official record
Conditions
Oral Dysplasia, Leukoplakia Oral, Leukoplakia
Interventions
Imiquimod (topical use)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 21, 2026, 8:41 PM EDT
Terminated Not applicable Interventional Results available

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

NCT00470392
View directory record Official record
Conditions
Psoriasis
Interventions
Imiquimod, Clobetasol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

NCT00899574
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Imiquimod
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

NCT00707174
View directory record Official record
Conditions
Cancer, Lentigo Maligna
Interventions
Imiquimod Cream, Tazarotene Cream 0.1%
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Results available

Bioequivalence Study of Two Imiquimod Cream 5%

NCT00828568
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Gilbert, Arizona • Tempe, Arizona • Tuscon, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

NCT00894647
View directory record Official record
Conditions
Actinic Keratosis
Interventions
imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • Saint Petersberg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00735462
View directory record Official record
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 21, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Imiquimod for Preventing Keloid Recurrence

NCT03760250
View directory record Official record
Conditions
Keloid
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

NCT00079300
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
imiquimod, conventional surgery
Drug · Procedure
Lead sponsor
National Naval Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 21, 2026, 8:41 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

NCT02234921
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Cyclophosphamide, DRibble Vaccine, HPV Vaccinations, Imiquimod
Drug · Biological
Lead sponsor
UbiVac
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

NCT00116649
View directory record Official record
Conditions
Keratosis
Interventions
imiquimod cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Encino, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

NCT00948428
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod, Aldara™, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Hot Springs, Arkansas • Fresno, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

NCT00605176
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, Placebo
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Fremont, California • Los Angeles, California • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 With or Without Topical Aldara in Healthy Adults

NCT03472976
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 21, 2026, 8:41 PM EDT
Enrolling by invitation Phase 1 Interventional

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

NCT02600949
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy, Computed Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

NCT01502020
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, 3.75%, Vehicle Cream
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 21, 2026, 8:41 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726
View directory record Official record
Conditions
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions
GTL001+, Aldara
Drug
Lead sponsor
Genticel
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 21, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

NCT01909752
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cyclophosphamide, DRibble vaccine, Imiquimod, GM-CSF, HPV vaccine
Drug · Biological
Lead sponsor
UbiVac
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 21, 2026, 8:41 PM EDT